Hep C Discussion Forum

Treatment for 12 weeks with a coformulation of sofosbuvir and ledipasvir led to sustained response for all HIV/HCV coinfected patients with genotype 1 hepatitis C followed for 12 weeks post-treatment, according to interim findings from the ERADICATE study presented at the 49^th EASL International Liver Congress in London.

Anu Osinusi from the U.S. National Institute of Allergy and Infectious Diseases and colleagues tested a once-daily fixed-dose combination pill containing the recently approved HCV polymerase inhibitor sofosbuvir (Sovaldi) plus the NS5A inhibitor ledipasvir (400/90mg) in patients coinfected with HIV and hepatitis C.

Historically, HIV/HCV coinfected people have not responded as well to interferon-based therapy as HIV-negative people with HCV alone, but recent data suggest that interferon-free direct-acting antiviral regimens may be equally effective in people with HIV. The Photon - 1 study testing sofosbuvir plus ribavirin found that coinfected people had sustained virological response rates at 12 weeks post-treatment (SVR12) similar to those previously seen in HCV monoinfected patients.

http://www.hepctrust.org.uk/News_Resources/news/2014/April/Sofosbuvir+ledipasvir+produces+early+cure+for+100+of+HIV+HCV+coinfected+patients